| Abstract:Objective: To study the effective components and mechanism of Yinjia Tablet in the treatment of pelvic inflammatory disease. Methods: The chemical constituents of Yinjia Tablet were identified by UPLC-Q-Exactive Orbitrap MS technology combined with literature and reference substance comparison. The intersection targets of chemical components and pelvic inflammatory disease were imported into String database to construct protein-protein interaction (PPI) network. Gene ontology (GO) functional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways enrichment analysis was performed through the DAVID database ; Cytoscape 3.9.1 software was used to construct the visualization map of ' medicinal materials-components-targets-pathways '. Molecular docking was performed using Maestro 11.9 software. Results: A total of 58 chemical constituents were identified in Yinjia Tablet, including flavonoids, organic acids, terpenoids and alkaloids. Five core targets of teroid receptor coactivator (SRC), heat shock protein 90 alpha family class A member 1 (HSP90AA1), phosphoinositide-3-kinase regulatory subunit1 (PIK3R1), signal transducers and activators of transcription 3 (STAT3) and mitogen-activated protein kinase 3 (MAPK3) were obtained by PPI analysis. KEGG results showed that Yinjia Tablet mainly played a role through phosphatidylinositol 3 kinase-protein kinase B (PI3K-Akt), mitogen-activated protein kinase (MAPK) and other pathways. Molecular docking results showed that the docking conformation of luteoloside, kaempferol, luteolin, diosmetin and other components with SRC, HSP90AA1, PIK3R1 and other five core targets was stable. Conclusion: Yinjia Tablet may play a role in the treatment of pelvic inflammatory disease by regulating PI3K-Akt, MAPK and other pathways through active components such as luteoloside, kaempferol, luteolin, diosmetin and apigenin. |
